FDA Advises Virtual Ban On Amgen, J&J Anemia Drugs

Law360, New York (March 13, 2008, 12:00 AM EDT) -- A U.S. Food and Drug Administration panel reportedly voted Thursday to ban the use of anemia drugs, including Amgen Inc.'s Aranesp and Epogen and Johnson & Johnson's Procrit, in most cancer patients.

The Oncologic Drugs Advisory Committee voted 9-5 that the drugs shouldn't be used at all in patients with breast cancer or head and neck cancer, according to Dow Jones.

The panel advised that the drugs, known as erythropoiesis-stimulating agents, should only be part of a treatment if the patient has advanced metastatic cancer or...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.